Changes to AstraZeneca Board of Directors

Regulatory News Service

6 March 2017 07:00

AstraZeneca today announced that Philip Broadley will be proposed to shareholders for election as a Non-Executive Director of AstraZeneca PLC at the Company’s Annual General Meeting (AGM) on 27 April 2017. On election, the Board proposes appointing Mr Broadley as a member of the Audit Committee.

Ann Cairns, a Non-Executive Director, will step down from the AstraZeneca Board and as a member of the Audit Committee with effect from the end of the AGM on 27 April 2017.

Leif Johansson, Chairman of AstraZeneca, said: “On behalf of the Board, I’d like to thank Ann for her contribution to AstraZeneca, both as a Board member and as a member of the Audit Committee over the last three years. We wish her all the best for the future. I’m delighted that the Board is proposing Philip Broadley for election as a Non-Executive Director. His significant international business and financial experience will prove a valuable addition to the Board and we look forward to welcoming him.”  

Subject to his election by shareholders, Mr Broadley will join the Board and the Audit Committee with effect from the end of the AGM on 27 April 2017. The Notice of AGM is due to be published on or around 16 March 2017.

In relation to Mr Broadley’s proposed election, no disclosure obligations arise under paragraphs (2) to (6) of LR 9.6.13 R of the UK Listing Authority's Listing Rules. Details of directorships to be disclosed under paragraph (1) of LR 9.6.13 R are included within the biographical details below.

Philip Broadley – biographical details

Philip has significant financial and international business experience, having previously been Group Finance Director of Prudential plc for eight years until 2008 and of Old Mutual plc for six years until 2014. He started his career at Arthur Andersen where he was a partner for seven years. He is a past Chairman of the 100 Group of Finance Directors in the UK. He is a Fellow of the Institute of Chartered Accountants in England and Wales. He graduated in Philosophy, Politics and Economics from St Edmund Hall, Oxford and has an MSc in Behavioural Science from the London School of Economics.

Philip is a Non-Executive Director of Legal & General Group plc and chairs its Audit Committee. He is a member of the Code Committee of the UK Takeover Panel. He is a member of the Oxford University Audit Committee, Treasurer of the London Library and a governor of Eastbourne College.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of Autoimmunity, Neuroscience and Infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit and follow us on Twitter @AstraZeneca.


Media Enquiries





Esra Erkal-Paler


+44 203 749 5638

Vanessa Rhodes


+44 203 749 5736

Karen Birmingham


+44 203 749 5634

Rob Skelding


+44 203 749 5821

Jacob Lund


+46 8 553 260 20

Michele Meixell


+1 302 885 2677





Investor Relations



Thomas Kudsk Larsen


+44 203 749 5712

Craig Marks

Finance, Fixed Income, M&A

+44 7881 615 764

Henry Wheeler


+44 203 749 5797

Mitchell Chan


+1 240 477 3771

Lindsey Trickett

Cardiovascular & Metabolic Diseases

+1 240 543 7970

Nick Stone


+44 203 749 5716

Christer Gruvris

Autoimmunity, neuroscience & infection

+44 203 749 5711

US Toll-Free


+1 866 381 7277


Adrian Kemp
Company Secretary
AstraZeneca PLC


  • Regulatory